Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Aptevo contributes its multispecific antibody platforms (ADAPTIR and ADAPTIR-FLEX technologies) alongside development expertise. Niowave receives an initial…
Niowave made an at-the-market equity investment in Aptevo at closing, representing an initial ownership position of 7.9%, with the potential to build a…
Aptevo Therapeutics (Nasdaq: APVO) and Niowave, Inc. announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs.…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Aptevo Therapeutics (Nasdaq: APVO) and Niowave entered a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs, with the first program directed at Nectin-4 and pairing Aptevo's proprietary molecule APVO455 with Niowave's Actinium-225 and additional radioisotopes. Executed concurrently were a collaboration agreement (commencing with a proof-of-concept study), a supply agreement under which Niowave supplies radioisotopes to Aptevo, and a stock purchase agreement. At closing Niowave made an at-the-market equity investment giving it an initial ~7.9% ownership position (based on shares outstanding as of May 13, 2026), with the potential to build to up to 19.99% through warrant exercises at a premium and future purchases of Aptevo common stock. No transaction dollar value was disclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Aptevo Therapeutics Inc. / Niowave, Inc. (this deal) | 2026 | — | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2026 deals · Oncology deals